Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21


51709 items
4:56 PM, Sep 13, 2018  |  BC Extra | Company News

ICER panel: hATTR treatments have low value

The Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council (CEPAC) voted unanimously in separate tallies that the long-term value for money was low for hATTR treatments from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)...
4:55 PM, Sep 13, 2018  |  BC Extra | Company News

Management tracks: Real Endpoints, Poxel, Travecta

Reimbursement consultancy Real Endpoints LLC hired Jeff Berkowitz as CEO. He replaces Roger Longman who becomes chairman. Berkowitz was EVP at UnitedHealth Group Inc. (NYSE:UNH), where he was CEO of its Optum International business and...
3:56 PM, Sep 13, 2018  |  BC Extra | Company News

Patient groups urge CVS to reconsider ICER-restricted formulary

At least 94 patient groups and individuals signed a letter urging CVS Health Corp. (NYSE:CVS) President and CEO Larry Merlo to reconsider a new formulary that would be restricted to drugs deemed cost effective by...
3:51 PM, Sep 13, 2018  |  BC Extra | Financial News

Surface Oncology execs join MPM

MPM Capital hired Detlev Biniszkiewicz and Scott Chappel as executive partners. They will be responsible for identifying and evaluating new oncology investment opportunities for MPM, as well as portfolio oversight. Biniszkiewicz and Chappel are former executives...
3:19 PM, Sep 13, 2018  |  BC Extra | Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will be...
2:31 PM, Sep 13, 2018  |  BC Extra | Company News

Boehringer adds to immuno-oncology pipeline with ViraTherapeutics acquisition

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised an option to acquire oncolytic virus company ViraTherapeutics GmbH (Innsbruck, Austria). Boehringer gained the option under a 2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its...
2:02 PM, Sep 13, 2018  |  BC Extra | Company News

FDA approves AZ's hairy cell leukemia drug

FDA approved Lumoxiti moxetumomab pasudotox-tdfk from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat relapsed or refractory hairy cell leukemia in adults who have received at least two prior systemic therapies, including a purine nucleoside analog. Lumoxiti, an...
1:32 PM, Sep 13, 2018  |  BC Extra | Politics & Policy

Woodcock: single FDA center for rare diseases could be 'negative' to rare disease cause

FDA's Center for Drug Evaluation and Research (CDER) Director Janet Woodcock advised against a single FDA Center of Excellence (COE) for rare diseases. Woodcock made the remarks while speaking at the EveryLife Foundation for Rare...
1:11 PM, Sep 13, 2018  |  BC Extra | Preclinical News

Paper-based method for POC metabolite diagnosis

A metabolite detection method described in a Science paper published Thursday could provide clinicians with a paper-based point-of-care diagnostic that could potentially measure 42 metabolites implicated in a range of diseases. The method could improve...
10:43 AM, Sep 13, 2018  |  BC Extra | Financial News

Hua raises $110M in Hong Kong IPO

Diabetes company Hua Medicine Ltd. (HKSE:2552) raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8 million shares at HK$8.28. EVP and CFO George Lin said the offering, which priced at the...